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CDObjective: Robotic totally endoscopic coronary artery bypass of the left anterior
descending artery has been introduced in the clinical setting using a wrist-enhanced
computer-assisted device to provide a minimally invasive therapeutic approach. Early
clinical results were focused on the initial hospital course of patients. This report
describes the first 5-year follow-up of patients after totally endoscopic coronary artery
bypass in a single center.
Methods: From May 1999 to June 2001, 41 patients (36 male, 5 female; mean age
60.6 6 8.9 years) underwent totally endoscopic coronary artery bypass for isolated
high-grade lesions of the left anterior descending coronary artery by means of the
da Vinci system (Intuitive Surgical, Inc, Mountain View, Calif). Clinical follow-up
was performed 5 years after the operation. End points of the follow-up were freedom
from major adverse events such as death, myocardial infarction, and repeated revas-
cularization of the left anterior descending artery.
Results:Hospital survival was 100%. Overall survival after 5 years was 92.7% (38/41
patients). Three (7.3%) patients died of noncardiac causes. Freedom from reinterven-
tion of the left anterior descending artery after a mean of 696 7.4 months was 87.2%
(36/41 patients). Freedom from any major adverse events during the whole follow-up
was 75.7% (31/41 patients).
Conclusion: Endoscopic surgery on the beating heart remains the ultimate goal for
minimally invasive coronary artery surgery. The clinical outcomes and need for rein-
tervention of the target vessel leave room for improvement and may be considered
reflective of early experiences typically associated with dramatic departure from con-
ventional therapy. Moving forward, advances in instrumentation and anastomotic
technology seem to be essential for reproducible and reliable coronary anastomosis
in a totally endoscopic approach.
R
obotic technology was introduced into cardiac surgery in 1999. The da Vinci
(Intuitive Surgical Inc, Sunnyvale, Calif) telemanipulator system was de-
signed to allow the surgeon to perform totally endoscopic coronary artery
bypass grafting (TECAB).1-3 These design criteria were validated in the initial clinical
trials resulting in European and Food and Drug Administration approval for mini-
mally invasive cardiac surgery. These early trials mainly focused on initial outcomes
until hospital discharge.1-4
Long-term assessment of this surgical approach is still pending. The Heart Center
Dresden was one of the early adopters of this technology and performed the TECAB
procedure in a number of patients requiring single-vessel revascularization, initially
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CDAbbreviations and Acronyms
LAD 5 left anterior descending coronary artery
MACE 5 major adverse cardiac events
MIDCAB 5 minimally invasive direct coronary artery
bypass
TECAB 5 totally endoscopic coronary artery bypass
on-pump and later using the off-pump technique.3 The fol-
lowing describes the 5-year clinical results from this initial
single-center TECAB series.
Patients and Methods
Forty-one patients (36 male, 5 female; average age 60.6 6 8.9 years)
with single- (95.2%) and double-vessel (4.8%) coronary artery disease
involving primarily the left anterior descending artery (LAD) under-
went a TECAB procedure with a wrist-enhanced coronary anasto-
mosis by means of the da Vinci system (Intuitive Surgical, Inc,
Mountain View, Calif) between May 1999 and June 2001. The 41
patients accounted for 1.2% of all patients who underwent surgical
treatment for coronary artery disease during the same period at the
same institution.
Demographic data of these patients are presented in Table 1 and
show that this patient cohort presented a low rate of comorbidities
and risk factors, as illustrated by the comparably low EuroSCORE
of 2.16 0.1. The operative data regarding target vessel and conduit
selection are shown in Table 2.
The initial 8 (19.6%) patients received the TECAB technique on
the arrested heart with an endovascular bypass system. In 33 (80.4%)
patients a beating-heart off-pumpTECABprocedurewas performed.
Stabilization was accomplished with 4 different iterations of
endoscopic stabilizers, all of which need to be considered early pro-
totypes (Figure 1).
Follow-up information on patients was obtained in June 2006
and was complete in all 41 patients having undergone this particular
procedure. The mean follow-up period was 69 6 7.4 months with
a range of 60 to 85 months.
Sampling of data was accomplished by reviewing hospital
records and by performing a telephone interview with the patient
directly, the patients’ relatives, or the patients’ referring physicians.
This clinical evaluation was approved by the ethics committee of
the University of Leipzig (‘‘Study on the Clinical Use of a Telema-
nipulator in Minimally Invasive Cardiac Surgery’’; Int. Reg. No.
721, approval date May, 19, 1998).
Data collected included mortality, myocardial infarction, and
reintervention of the LAD. The presence of a myocardial infarction
was determined on the basis of electrocardiographic changes,
elevated troponin I levels, and creatinine/creatinine myoglobin frac-
tions. These end points were incorporated into an overall assessment
of the incidence of major adverse events. Major adverse cardiac
events (MACE) were defined as myocardial infarction, reinterven-
tion of the LAD, and cardiac-related mortality.
Results
Overall survival was 92.7% (38/41 patients). The 3 deaths
were due to noncardiac-related causes: 2 patients died of gas-858 The Journal of Thoracic and Cardiovascular Surgery c Aptrointestinal carcinoma and 1 patient died of gastrointestinal
bleeding and shock.
Two myocardial infarctions (4.8%) occurred in the fol-
low-up period. One myocardial infarction occurred within
the first 6 months after the operation and the other 19 months
postoperatively. In both cases the infarct was not located
within the region of the bypassed target vessels.
Postoperative angiograms are available from 14 (35%) pa-
tients. Reintervention of the LADwas necessary in 5 (12.2%)
patients. Two (4.8%) patients required reoperation of the
target vessel for graft occlusion. Surgical revascularization
was performed by the median sternotomy approach. Two pa-
tients received an angioplasty of the LAD (4.8%) owing to
significant anastomotic stenosis and in 1 patient owing to
a de novo lesion of the distal LAD. Freedom from reinterven-
tion of the LAD was 87.8% after a median of 69 months. On
the basis of all available postoperative angiography data, the
overall patency rate of the LAD was 71.4% (10/14).
Overall freedom frommajor adverse events for this follow-
up was 31 (75.6%) of 41, excluding noncardiac death (34/41,
82.9%; Figure 2). Overall results are displayed in Table 3.
Discussion
With the clinical introduction of the da Vinci system, sur-
geons are given the opportunity for the first time in history
to perform coronary surgery in a closed chest fashion. The
following analysis demonstrates that endoscopic revascular-
ization of coronary arteries requires further evaluation.
TABLE 1. Baseline characteristics
Variable TECAB group (n 5 41)
Age (y) 60.6 6 8.9
Male sex, No. (%) 36 (88)
Body mass index (kg/m2) 26.5 6 0.6
Cardiovascular risk factors, No. (%)
Current smoking 14 (34)
Hypertension 33 (82)
Diabetes mellitus 12 (30)
Hypercholesterolemia 35 (85)
Previous myocardial infarction 4 (10)
Left ventricular ejection fraction 67.6 6 1.45
EuroSCORE 2.1 6 0.1
TABLE 2. Grafted vessels and used conduits
Technique Grafted vessels and used conduits
TECAB (on pump, n 5 8) LITA–LAD (n 5 7)
RITA–LAD, LITA–OM (n 5 1)
TECAB (off pump, n 5 33) LITA–LAD (n 5 30)
RITA–LAD, LITA–D (n 5 2)
RITA–LAD, LITA–OM (n 5 1)
TECAB, Totally endoscopic coronary artery bypass; LITA, left internal
thoracic artery; LAD, left anterior descending artery; RITA, right internal
thoracic artery; OM, obtuse marginal; D, diagonal.ril 2008
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CDThe freedom from MACE excluding noncardiac-related
death was 82.9%. The small number of patients studied,
the lack of angiographic follow-up in this report, and the
lack of other long-term clinical follow-up studies after TE-
CAB procedures in the medical literature make it difficult
to interpret these results. In 2007, Holzhey, Jacobs, and
Mochalski5 reported results from a 7-year follow-up study
in 1300 patients after minimally invasive direct coronary ar-
tery bypass (MIDCAB) where the freedom from MACE was
83%. In 2006, Argenziano, Katz, and Bonatti4 reported from
a multicenter study on the safety and efficacy of the da Vinci
system. In this study, patients underwent a robotic TECAB
procedure on-pump. There was no mortality and low mor-
bidity. Three-month angiography, performed in 76 patients,
revealed significant anastomotic stenoses (.50%) or occlu-
sions in 6 patients. Overall freedom from reintervention or
angiographic failure was 91%.
Up to now, endoscopic revascularization on the beating
heart has not translated into a routine procedure within the
past 6 years, although significant progress in the technical
aspects of the procedure have certainly been made.
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Figure 2. Freedom of cardiac related major adverse events (82.9%)
after TECAB.The Journal of ThorThe need for high-quality outcomes in conjunction with
the use of innovative concepts such as robot-assisted surgery
will continue to require a significant technologic and inte-
llectual investment to ensure reproducibility of such a com-
plex procedure.
With the rapid evolution of surgical techniques and tech-
nologies, the optimal treatment of isolated LAD disease
remains extensively debated. Durability and invasiveness of
the surgical approach have to be balanced with the relatively
less invasive percutaneous treatment, which is often associ-
ated with the need for repeat revascularization procedures.6
The main focus of any bypass procedure, regardless of the
technique used, should be on the quality of the coronary anas-
tomosis. In 2003, Jacobs and associates7 presented data de-
scribing limitations of telemanipulators such as incomplete
motion tracking, delays in tracking, and information tracking.
These limitations are likely to negatively affect the quality of
an anastomosis, particularly in beating-heart surgery. Sur-
prisingly, in our cohort no significant differences concerning
the outcome of on- and off-pump operations could be de-
tected. This might be due to the small number of patients.
TABLE 3. Clinical follow-up results after totally endo-
scopic coronary artery bypass surgery in a median of
69 6 7.4 months
End point TECAB (n 5 41)
Death, No. (%) 3 (7.3)
Cardiac 0
Noncardiac 3 (7.3)
Myocardial infarction [no.] (%) 2 (4.8)
,6 mo 1 (2.4)
.6 mo 1 (2.4)
Myocardial infarction and cardiac death, No. (%) 2 (4.8)
Repeated revascularization of the target
vessel, No. (%)
5 (12.2)
,6 mo 3 (7.3)
.6 mo 2 (4.8)
Any major adverse event, No. (%) 10 (24.4)
TECAB, Totally endoscopic coronary artery bypass.acic and Cardiovascular Surgery c Volume 135, Number 4 859
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conversion rates in later series.4 However, to meet the high
standards of coronary revascularization, the anastomotic
technique should be adjusted to meet the needs of intratho-
racic limited space surgery.
In a review of modern anastomotic technology, Carrel8
correctly stated that the surgical limitations of the minimally
invasive revascularization procedure are related to the
inability to perform a conventional hand-sewn coronary
anastomosis. He mentioned that there is an urgent need to
define the performance objectives of such systems as well
as the general criteria for proper and comparable evaluation
and validation of different systems in animal models and sub-
sequently in controlled prospective clinical studies.
In 2005 our group9 published the results from the pivotal
clinical trial using the Cardica C-Port distal anastomosis sys-
tem (Cardica Inc, Redwood City, Calif). Despite the use of
this novel device in often small coronary targets with inferior
runoff, the discharge and 6-month angiographic patency re-
sults were found to be superior to historical data from the
published literature on vein graft patency using conventional
hand-sewn techniques. We believe this technology offers
a lot of promise for resurgence in TECAB.
Besides anastomotic technology and refinements in stabi-
lization systems, further improvements in technology will be
needed. Target vessel identification can be challenging in
some patients.10 Bonatti and associates11 summarized techni-
cal difficulties their group has encountered in TECAB proce-
dures. These included difficulties with port hole placement,
port hole bleeding, left internal thoracic artery damage during
harvesting, epimyocardial lesions during target vessel prepa-
ration, problems with the anastomoses, and, in patients
undergoing on-pump operations, technical difficulties with
cannula and occlusion balloon placement. It is therefore
safe to say that intense technologic and procedure-related de-
velopment will be necessary to reduce the rate of undesirable
events and to significantly improve the ease of use.
Currently, TECAB procedures add significantly to the
overall procedure costs. This has also been true for the intro-
duction of radically different procedures such as laparoscopic
and thoracoscopic interventions. Although initially this may
appear prohibitive, in the latter two examples it has not hin-
dered a change in operative standards, and with time and
sufficient procedural volume, the costs tend to come down
and can often be justified by a reduction in hospital stay, pa-
tient morbidity, and a dramatic decrease in invasiveness. We
therefore believe it would be premature to discard the devel-
opment of TECAB procedures at this time on the basis of
current health care economics.
Conclusions
Since its introduction in 1999, the TECAB approach to LAD
revascularization is still restricted to a few specialized cen-860 The Journal of Thoracic and Cardiovascular Surgery c Aprilters. With this kind of history, TECAB procedures cannot
be considered novel, and overall the adoption of this technol-
ogy has been disappointing and slow for coronary surgery.
Widespread adoption is most certainly hindered by the tech-
nical challenges associated with this complex procedure.
This is especially true with respect to the creation of the vas-
cular anastomosis in a closed chest setting. These challenges,
however, are inherent to any novel, disruptive therapy and
have been overcome in comparable interventions such as
arthroscopic or laparoscopic surgery.
We strongly believe that as cardiac surgeons we have
a mandate to continue to refine our technique with the end
goal of developing a standard on- or off-pump TECAB pro-
cedure for routine use in patients with isolated high-grade
LAD lesions. The combination of the excellent coronary ar-
tery bypass graft outcomes with a truly less invasive proce-
dure is clearly beneficial to patients.
Limitations of this study include the lack of angiographic
patency assessment in the majority of the patients studied.
The small number of patients also limits the final conclusions
that can be drawn from this experience.
The challenge will be how to refine the technique and
accelerate the learning without compromising short- and
long-term outcomes. The clinical outcomes in these proce-
dures need to be comparable with those obtained after other
minimally invasive surgical revascularization strategies for
isolated LAD lesions4,5 to justify further exploration of this en-
doscopic form of therapy. However, there is significant room
for improvement, and we believe further technical develop-
ments, such as anastomotic devices, are mandatory to achieve
the patency and morbidity outcomes we have become accus-
tomed to obtaining after the standard sternotomy approaches.
Limitations
A number of limitations in this study need to be taken into
account. The TECAB technique was performed with a first-
generation telemanipulator.
The implementation of a completely new device, tech-
nique, and surgical approach was certainly associated with
a learning curve in all steps of the procedure, especially
with regard to the endoscopic creation of the vascular anasto-
mosis, which included learning how to identify, dissect, and
control the target vessel.
Commercially available endoscopic stabilizers had not yet
been developed; therefore, the quality of the anastomoses
was probably negatively affected by the use of these early
endostabilizer prototypes (Figure 1). The procedure was
evolving during this initial series, resulting in a large number
of variations in the surgical techniques used.
The data obtained were from a single center; therefore, our
technique did not benefit from the knowledge obtained by
other centers during the same period. Follow-up obtained
in this series was restricted to clinical outcome and did not2008
Kappert et al Surgery for Acquired Cardiovascular Disease
A
CDinclude complete long-term angiographic assessment of pa-
tency. Finally, the number of patients enrolled was small.
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Discussion
Dr Ralph J. Damiano, Jr (St. Louis, Mo). I would like to con-
gratulate Dr Kappert and his colleagues for providing long-term fol-
low-up on this very important cohort of patients and also for their
pioneering work in the field.
It is interesting, now, getting on almost 10 years since the first
robotic coronary procedures were done in both Europe and the
United States, that we can begin to look at some long-term fol-
low-up. It also is a bit humbling to look at how small the series
have remained. This probably is the biggest word of caution before
people go out and embark on these programs themselves.
I have a number of questions. I will ask them one at a time.
First, robotic technology was introduced to enhance dexterity.
This was the basic premise for the adoption of these very expensive
systems. However, it was very clearly shown in an experimental
model by Dr Volkmar Falk several years ago, which I am sure
you are aware of, that robotic instrumentation actually is a lot worse
than doing it by hand in the beating-heart environment; that is, the
error rate with robotics was significantly higher than with manual in-
strumentation, so actually it reduced dexterity in this environment.
Also, in the clinical trial of the ZEUS system (Computer Motion,
Inc, Goleta, Calif), which was not as sophisticated a system as theThe Journal of ThoIntuitive da Vinci system, the off-pump patency was significantly
worse.
You had two groups of patients. In the first group the heart was
arrested and in the second it was beating. If you separated the groups
and told us what the major adverse event rate or target revasculari-
zation rate was just on your beating-heart group, can you separate
the 8 arrested-heart patients from the beating-heart ones? I think
that is an important differentiation for this technology. These sys-
tems do not seem to respond well when there is any type of motion.
Have you looked at these groups separately?
Dr Kappert. I think Dr Cichon can answer this question. He did
nearly 100% of the procedures by himself.
Dr Romuald Cichon (Dresden, Germany). Thank you very
much. I am the senior partner of my friend.
The first part of the question concerned dexterity. As you know,
we have augmentation of almost 10 times using this kind of a robotic.
We have a filter to mask the tremor. Thus I do not believe that with
good stabilization dexterity will be lessened with this system. How-
ever, the crucial aspect of this answer would be good stability and
good stabilization of the cardiac wall.
Your second question concerned off-pump versus on-pump
techniques. Of course, we started with the on-pump technique in
the very early days. But somehow, aiming to the goal of minimally
invasive cardiac surgery and going back to the on-pump era felt
somehow unfair. After we achieved a good sequence to the proce-
dure, which allowed us, in a considerable time, to perform the whole
operation, we switched to the off-pump technique. There was quite
a rocky ride. At that time, we had only the No. 4 prototype of the
stabilizer that we were developing. Now we have the No. 7 proto-
type, as I recall. This is the kind of development that we got.
Basically, thatwas theworst part of the story.With augmentationof
up to 10 times, even a very small movement seems like an earthquake.
Dr Damiano. I guess I still did not get an answer to my question.
If you looked at the stenotic vessels and the ones that needed revas-
cularization, were they all in the beating-heart group? If so, your de-
nominator then is much less and then your rate of major adverse
events may be much higher.
My question is, were the adverse events clustered in the beating-
heart population? Both experimental data would suggest it may be
worse, as did the initial clinical work with the ZEUS system that
has been published previously. If you looked at it separately, what
did you see?
DrCichon.Unfortunately, we did not see any difference. In both
of the groups, we had one graft that failed, which probably was
related to poor handling in the preparation of both of the thoracic ar-
teries. Again, this series of 8 cases and then 30 cases is too small to
allow us to very distinctly differentiate those complications. The
only difference that you have seen was the progressive coronary dis-
ease in the group of off-pump operations, but in a natural way there
were simply more patients involved.
Dr Damiano. If we had catheterization data on everyone, we
really could get a good idea of patency. Unfortunately, few patients
in this trial had a postoperative catheterization. But you actually do
have catheterization data on, I would estimate, at least 7 of the pa-
tients, because those are the patients who had either a myocardial in-
farction or target vessel revascularization. If you just looked at the
catheterization data you have, what would be the patency rate of
that small cohort?racic and Cardiovascular Surgery c Volume 135, Number 4 861
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DrDamiano.And stenosis. You are obviously picking a selected
group. But you do have catheterization data on a part of this group,
so I was surprised not to see that presented.
Dr Cichon. We treated those patients as we did any other pa-
tients with coronary disease treated in our clinic. We did not perform
coronary angiography in all the patients. Our practice is to screen
a patient for angiography if there is an ischemic event. Otherwise,
we do not do angiography. Thus the 7 patients whom we have
seen are the patients who had a problem with ischemia. In most
cases, angiography was done more than 6 months after the opera-
tion. Those are the data that were presented.
DrDamiano. It just was unclear. You did more than one graft on
some of those patients, so I was just wondering whether you had the
total number of grafts that were visualized by angiography at late
follow-up and how many of those had either stenosis or occlusion.
This would be another interesting number. It is very possible in your
group that you may have had a number of asymptomatic occlusions
that you would have been unaware of had the patients not come back
for follow-up.
DrCichon.Well, of course, we can exclude it; however, angiogra-
phy is not the only parameter of cardiac ischemia or the diagnosis of
cardiac ischemia.Wehaveother parameters thatweused as our routine.
Dr Damiano. I did not see those data. Are you saying that all the
patients had routine stress tests?
DrCichon.Well, of course, they had echocardiography, electro-
cardiography, and enzyme monitoring. All of those patients were
monitored in the standard manner used in every patient in our clinic.
Dr Damiano. I guess I’m just trying to get a better feel for what
was actually the patency rate in this cohort.
I would like to finish with a question. This is a very highly se-
lected group, 1% of your volume. It is all patients with principally
single-vessel disease, and I am sure you mentioned that you took
even the best of that group. This was a lower risk group than your
normal cohort, and I assume they all had an excellent-quality
LAD or you would not have put them in this initial trial. With this
in mind, I would like to emphasize a word of caution. The reinter-
vention rate of 12% at 5 years in this type of a cohort, particularly
since there was not good angiographic follow-up, is not great. I
do agree with your final comment that these procedures should be
approached cautiously. This is hardly being done anywhere in the
world, but certainly if it is being done, it should be done in very
highly specialized centers that have tremendous dedication, as you
have had, to try to develop the technology. My own impression is
that there are very inherent limitations of robotics. The present
robotic systems in a beating-heart environment actually decrease
your dexterity.
Besides anastomotic devices, which I agree would be an im-
provement, what else could be enhanced with these robotic
systems that could improve the results in the beating-heart
situation?
DrKappert. I believe the first (and very important) thing that we
missed from that day, basically up to today, is a sufficient number
and quality of synergic instrumentation. At that time we started862 The Journal of Thoracic and Cardiovascular Surgery c Aprwith 9 instruments suitable for the robotic system. Today we
have, I believe, 40, and we are not done by far with the instrum-
entation. That is probably the most important thing that we have
to improve. I see an immense area for industry to develop. However,
I know it is very difficult at that time.
On the other hand, the overall improvement of the system, with
a fourth arm right now, is also increasing the ability to use this in
a much safer manner.
Dr Valavanur Subramanian (New York, NY). I have three
points of not just caution, but help, from the days of MIDCAB.
Very early on, we showed that a good stabilization equals a good pa-
tency. We have graded the stabilization as A, B, and C and have
looked at that. By that I mean not only the mechanical stabilization
but also the internal stabilization of the artery that you are going to
sew. We presented information at the American Heart Association
meeting in 1996 about the shunted group and nonshunted group
and a MIDCAB, and there is tremendous difference.
Second, anybody who does beating-heart surgery through a min-
imally invasive approach must have a controlled angiogram. By that
I mean I do not think you should have just a fixed, given patency.
We again did some work on looking at minimum luminal diameter,
waist stenosis, toe stenosis, and heel stenosis, just like interventional
cardiologists will do, because it did enhance our technical perfor-
mance to do a better MIDCAB operation. Thus I think it is not
enough to just have patency.
We also have some indication that it correlates very well with
a long-term patency late rate in our own group and the MIDCAB
group. Therefore, I would say that if you are going to do closed chest
heart surgery you must have a controlled angiogram in these pa-
tients, of some period, and evaluate it very carefully, not just the pa-
tency. I think you should look in the details of the anastomotic
milieu, the stenosis, where the stenosis is, and the luminal diameter,
just as interventional cardiologists do, who have perfected their stay-
ing technique, to a point where they do not believe that 30% is
enough. It is important for us to rigorously look at these techniques
to have good results. Unless you do that, you will not learn what the
problems are with TECAB and will not be able to improve.
Did you use a shunt in some of these patients? It does help you to
place the precise stitches. We are doing suture technique with the
TECAB. Does it help you to put a shunt in so that you can control
your anastomotic milieu?
Dr Cichon. Yes, we did use a shunt in some of those patients.
Dr Subramanian. Did you see a difference?
Dr Cichon. Not too much, because the main problem with the
suturing was still good stabilization. It did help us. However, the
mean anastomotic time was about 14 minutes, so we did not think
that we were going to do too much damage to the vessel.
Dr Vaughn A. Starnes (Los Angeles, Calif). I have just one
additional comment. Having worked with the robot a fair amount,
I think that the coupling devices will help with tactile feedback
and handling the tissues, handling the sutures. Sometimes I think
we create stenosis on the suture line by trying to use general methods
that we normally use with hand dexterity and I just do not think are
applicable with the robotic system.il 2008
